Adam M Mendizabal
Overview
Explore the profile of Adam M Mendizabal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levis M, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al.
Blood
. 2025 Jan;
PMID: 39775763
BMT CTN 1506 ("MORPHO"; NCT02997202) was a randomized phase 3 study of gilteritinib compared to placebo as maintenance therapy after hematopoietic stem cell transplantation (HCT) for patients with FLT3-ITD-mutated acute...
2.
Walters M, Eapen M, Liu Y, El Rassi F, Waller E, Levine J, et al.
Blood Adv
. 2024 Oct;
9(5):955-965.
PMID: 39471440
Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2 years after biologic assignment...
3.
Shindiapina P, Pietrzak M, Seweryn M, McLaughlin E, Zhang X, Makowski M, et al.
Front Immunol
. 2021 Sep;
12:700045.
PMID: 34539628
We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma,...
4.
Ambinder R, Wu J, Logan B, Durand C, Shields R, Popat U, et al.
Biol Blood Marrow Transplant
. 2019 Jul;
25(11):2160-2166.
PMID: 31279752
We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase II prospective multicenter trial. The primary endpoint was 100-day...
5.
Scott B, Pasquini M, Logan B, Wu J, Devine S, Porter D, et al.
J Clin Oncol
. 2017 Apr;
35(11):1154-1161.
PMID: 28380315
Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival...
6.
Ramireddy A, Brodt C, Mendizabal A, DiFede D, Healy C, Goyal V, et al.
Stem Cells Transl Med
. 2017 Mar;
6(5):1366-1372.
PMID: 28252842
Transendocardial stem cell injection in patients with ischemic cardiomyopathy (ICM) improves left ventricular function and structure but has ill-defined effects on ventricular arrhythmias. We hypothesized that mesenchymal stem cell (MSC)...
7.
Mendizabal A, Younes N, Levine P
Int J Hematol
. 2015 Nov;
103(1):70-8.
PMID: 26547571
Developing countries have a younger population of CML patients than developed countries. Patterns of age at diagnosis and incidence by geography and gross national income (GNI) are not well understood....
8.
Bolanos-Meade J, Logan B, Alousi A, Antin J, Barowski K, Carter S, et al.
Blood
. 2014 Aug;
124(22):3221-7.
PMID: 25170121
Corticosteroids are the accepted primary therapy for acute graft-versus-host disease (GVHD), but durable responses are seen in only about half of the patients. Blood and Marrow Transplant Clinical Trials Network...
9.
Suncion V, Ghersin E, Fishman J, Zambrano J, Karantalis V, Mandel N, et al.
Circ Res
. 2014 Jan;
114(8):1292-301.
PMID: 24449819
Rationale: Transendocardial stem cell injection (TESI) with mesenchymal stem cells improves remodeling in chronic ischemic cardiomyopathy, but the effect of the injection site remains unknown. Objective: To address whether TESI...
10.
Leen A, Bollard C, Mendizabal A, Shpall E, Szabolcs P, Antin J, et al.
Blood
. 2013 Apr;
121(26):5113-23.
PMID: 23610374
Virus-specific T cell (VST) lines could provide useful antiviral prophylaxis and treatment of immune-deficient patients if it were possible to avoid the necessity of generating a separate line for each...